本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Ascendis Pharma A/S

166.05
+1.400.85%
盤前166.050.00000.00%06:36 EDT
成交量:31.56萬
成交額:5,190.67萬
市值:99.37億
市盈率:-24.56
高:166.86
開:164.29
低:161.01
收:164.65
資料載入中...

公司資料

公司名字:
Ascendis Pharma A/S
交易所:
NASDAQ
成立時間:
2006
員工人數:
1017
公司地址:
Tuborg Boulevard 12,Hellerup,Capital Region of Denmark,Denmark
郵編:
2900
傳真:
- -
簡介:
Ascendis Pharma A/s成立於2006年9月21日。該公司是一家臨床階段的生物製藥公司,該公司運用其TransCon技術開發具有最佳的長效藥物療法的管道以解決大市場顯著未滿足的醫療需求。該公司正在開發其先導候選產品,TransCon人生長激素或生長激素TransCon,每周一次給藥治療生長激素缺乏症以及其他疾病。

董事

名稱
職位
Jan Moller Mikkelsen
President, Chief Executive Officer, Board Member and Executive Director
Michael Wolff Jensen
Chairman and Senior Vice President, Chief Legal Officer
Albert Cha
Director
Birgitte Volck
Director
James I. Healy
Director
Lars Holtug
Director
Lisa Bright
Director

股東

名稱
職位
Jan Moller Mikkelsen
President, Chief Executive Officer, Board Member and Executive Director
Dana Pizzuti
Senior Vice President, Development Operations
Flemming Steen Jensen
Senior Vice President, Product Supply
Jens Sigurd Okkels
Senior Vice President, Product Development
Jesper Hoiland
Senior Vice President, Global Chief Commercial Officer
Juha Punnonen
Senior Vice President, Head of Oncology
Kennett Sprogoe
Senior Vice President, Head of Innovation and Research
Lotte Sonderbjerg
Senior Vice President, Chief Administrative Officer
Mark Bach
Senior Vice President, Clinical Development and Medical Affairs for Endocrine Medical Sciences
Michael Wolff Jensen
Chairman and Senior Vice President, Chief Legal Officer
Scott T. Smith
Senior Vice President, Chief Financial Officer
Vibeke Miller Breinholt
Senior Vice President, Nonclinical Development and Bioanalysis
Peter Rasmussen
Vice President, Finance and Principal Accounting Officer